Safety and immunogenicity of a virus-like particle Chikungunya virus vaccine

Affiliations

¹ Department of Virology and Experimental Therapeutics, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil; Department of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, 15261 PA, USA. Electronic address: marques@pitt.edu.
² Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, 15261 PA, USA.

Comment

Ernesto T A Marques et al. Lancet. 2025.

. 2025 Apr 19;405(10487):1314-1315.

doi: 10.1016/S0140-6736(25)00571-9.

¹ Department of Virology and Experimental Therapeutics, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil; Department of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, 15261 PA, USA. Electronic address: marques@pitt.edu.
² Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, 15261 PA, USA.

No abstract available

Conflict of interest statement

We declare no competing interests.

Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial.
Tindale LC, Richardson JS, Anderson DM, Mendy J, Muhammad S, Loreth T, Tredo SR, Ramanathan R, Jenkins VA, Bedell L, Ajiboye P; EBSI-CV-317-005 Study Group. Tindale LC, et al. Lancet. 2025 Apr 19;405(10487):1353-1361. doi: 10.1016/S0140-6736(25)00372-1. Epub 2025 Mar 27. Lancet. 2025. PMID: 40158524 Clinical Trial.
Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial.
Richardson JS, Anderson DM, Mendy J, Tindale LC, Muhammad S, Loreth T, Tredo SR, Warfield KL, Ramanathan R, Caso JT, Jenkins VA, Ajiboye P, Bedell L; EBSI-CV-317-004 Study Group. Richardson JS, et al. Lancet. 2025 Apr 19;405(10487):1343-1352. doi: 10.1016/S0140-6736(25)00345-9. Epub 2025 Mar 27. Lancet. 2025. PMID: 40158526 Clinical Trial.